Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic
  • Search Hotels in Mill Valley

  • ROOMS:

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023

Company well-funded with expected cash runway into 3Q 2024

NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022.

“The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of the Abeona team’s extensive efforts,” said Vish Seshadri, Chief Executive Officer of Abeona. “This is an exciting time for Abeona as we are sharply focused on submitting a Biologics License Application for EB-101 to the U.S. FDA. With the additional capital raised after quarter-end, we are now well-funded into the third quarter of 2024, beyond the anticipated timing for potential BLA approval.”

Third Quarter and Recent Operating Highlights

EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

  • On November 3, 2022, Abeona announced positive topline data from the pivotal Phase 3 VIITAL study of investigational EB-101 in RDEB. The VIITAL study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. The Company intends to present more detailed results from this study at future medical meetings and in a peer-reviewed journal.
  • Based on the positive VIITAL topline results, the Company plans to submit a Biologics License Application (BLA) for EB-101 to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023. If the BLA is approved, Abeona may be eligible for a Priority Review Voucher (PRV), which can be used to receive expedited review by the FDA of a subsequent marketing application for a different product or sold to another company.
  • Long-term follow up data up to eight years and quality of life data from a completed Phase 1/2a study of EB-101 in RDEB were published in Orphanet Journal of Rare Diseases. The data showed that large chronic RDEB wounds treated with EB-101 had sustained wound healing with mean 5.9 years of follow-up, and long-term symptomatic relief, including reduction in pain and itch.

Preclinical programs

  • Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in AAV-based therapies for five undisclosed ophthalmic conditions. The Company has generated appropriate mouse models, produced research grade vectors, and started dosing mice in proof-of-concept studies to support possible pre-Investigational New Drug Application (IND) meetings with the FDA in early 2023.

Corporate highlights

  • On November 3, 2022, the Company announced a private placement financing with gross proceeds of $35.0 million. The private placement included participation from new and existing institutional investors.

Third Quarter Financial Results

Cash, cash equivalents, restricted cash and short-term investments totaled $23.5 million as of September 30, 2022. Net cash used in operating activities was $6.8 million for the third quarter of 2022, compared to $9.0 million in the second quarter of 2022. Abeona estimates that its current cash and cash equivalents, restricted cash and short-term investments plus the net proceeds from the private placement financing on November 3, 2022 are sufficient resources to fund operations into the third quarter of 2024.

Research and development (R&D) expenses for the three months ended September 30, 2022 were $5.5 million, compared to $9.1 million for the same period of 2021. General and administrative (G&A) expenses were $3.9 million for the three months ended September 30, 2022, compared to $5.8 million for the same period of 2021.

Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produced EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “plans,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of our Biologics License Application submission to the FDA for EB-101; our ability to fund operations with current cash and cash equivalents, restricted cash and short-term investments plus the net proceeds from our November 2022 private placement; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of any future meetings with the FDA or other regulatory agencies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

  For the three months ended September 30, For the nine months ended September 30,
   2022   2021   2022   2021 
License and other revenues $-  $-  $1,346  $- 
Royalties  -   -   350   - 
Research and development  5,490   9,056   22,693   25,923 
General and administrative  3,890   5,816   11,574   17,261 
Impairment of licensed technology  -   -   1,355   - 
Impairment of right-of-use lease asset  -   -   1,561   - 
Impairment of construction-in-progress  -   -   1,792   - 
Total expenses  9,380   14,872   39,325   43,184 
Loss from operations  (9,380)  (14,872)  (37,979)  (43,184)
Gain on settlement with licensor  -   6,743   -   6,743 
PPP loan payable forgiveness income  -   1,758   -   1,758 
Interest income  72   7   103   35 
Interest expense  (157)  (683)  (558)  (3,603)
Other income (expense)  (19)  3   (136)  (2)
Net loss $(9,484) $(7,044) $(38,570) $(38,253)
Deemed dividends related to Series A and Series B        
Convertible Redeemable Preferred Stock  -   -   (3,782)  - 
Net loss attributable to Common Shareholders $(9,484) $(7,044) $(42,352) $(38,253)
Basic and diluted loss per common share $(1.48) $(1.80) $(7.05) $(9.93)
Weighted average number of common        
shares outstanding – basic and diluted  6,421,245   3,924,024   6,009,902   3,853,318 
Other comprehensive income (loss):        
Change in unrealized gains (losses) related to available-for-sale debt securities  (4)  1   (11)  10 
Foreign currency translation adjustments  (6)  (9)  (6)  (9)
Comprehensive loss $(9,494) $(7,052) $(42,369) $(38,252)

Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

ASSETSSeptember 30,
 December 31,
Current assets:   
Cash and cash equivalents$5,733  $32,938 
Short-term investments 12,434   12,086 
Restricted cash 5,338   5,891 
Accounts receivable -   3,000 
Other receivables 1,047   - 
Prepaid expenses and other current assets 945   2,377 
Total current assets 25,497   56,292 
Property and equipment, net 6,606   12,339 
Right-of-use lease assets 6,638   9,403 
Licensed technology, net -   1,384 
Other assets 20   168 
Total assets$38,761  $79,586 
Current liabilities:   
Accounts payable$1,748  $4,325 
Accrued expenses 4,121   5,585 
Current portion of lease liability 1,810   1,818 
Current portion of payable to licensor 4,921   4,599 
Deferred revenue -   296 
Total current liabilities 12,600   16,623 
Payable to licensor 4,064   3,828 
Other long-term liabilities 200   200 
Long-term lease liabilities 6,484   7,560 
Total liabilities 23,348   28,211 
Commitments and contingencies   
Stockholders' equity:   
Preferred stock - $0.01 par value; authorized 2,000,000 shares;   
No shares issued and outstanding as of September 30, 2022 and   
December 31, 2021, respectively -   - 
Common stock - $0.01 par value; authorized 200,000,000 shares;   
7,671,351 and 5,888,217 shares issued and outstanding as of   
September 30, 2022 and December 31, 2021, respectively* 77   1,472 
Additional paid-in capital 709,590   705,570 
Accumulated deficit (694,210)  (655,640)
Accumulated other comprehensive loss (44)  (27)
Total stockholders' equity 15,413   51,375 
Total liabilities and stockholders' equity$38,761  $79,586 

* As of November 7, 2022, Abeona had 17,175,799 shares of common stock outstanding.


Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.